1. Home
  2. PUSA vs TCRX Comparison

PUSA vs TCRX Comparison

Compare PUSA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aureus Greenway Holdings Inc. Common Stock

PUSA

Aureus Greenway Holdings Inc. Common Stock

N/A

Current Price

$2.98

Market Cap

69.6M

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.75

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUSA
TCRX
Founded
N/A
2018
Country
United States
United States
Employees
47
142
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
49.4M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PUSA
TCRX
Price
$2.98
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
298.9K
869.2K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$2.65
$0.73
52 Week High
$4.45
$2.57

Technical Indicators

Market Signals
Indicator
PUSA
TCRX
Relative Strength Index (RSI) 22.21 33.79
Support Level N/A N/A
Resistance Level $3.90 $1.28
Average True Range (ATR) 0.27 0.08
MACD -0.06 -0.02
Stochastic Oscillator 10.00 2.61

Price Performance

Historical Comparison
PUSA
TCRX

About PUSA Aureus Greenway Holdings Inc. Common Stock

Aureus Greenway Holdings Inc own and operate two public golf country clubs in Florida. The golf country clubs include two golf-courses with over 13,000 yards of combined fairways, clubhouses boasting food and beverage options, aquatic golf ranges, and pro shops to assist any level of golfer and also host local golf leagues, golf-tournaments, and private events. Its golf country clubs is organized into four principal business segments: (i) golf recreation, retail golf products, and equipment and facilities rental, (ii) membership dues, (iii) food and beverage services. and (iv) ancillary services and amenities. All assets of the Company are located in Florida and all revenue is generated from Florida.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: